Insulin and insulin-like growth factor I up-regulate GLUT4 gene expression in fetal brown adipocytes, in a phosphoinositide 3-kinase-dependent manner

Biochem J. 1999 Feb 1;337 ( Pt 3)(Pt 3):397-405.

Abstract

Fetal brown adipocytes cultured in a serum-free medium, containing 5 mM glucose, expressed both GLUT4 and GLUT1 glucose transporters at the mRNA and protein level. Treatment with either insulin or insulin-like growth factor (IGF)-I at physiological concentrations up-regulates the expression of the GLUT4 gene, producing a time-dependent mRNA accumulation (7-fold increase at 24 h) and a 2.5-fold increase in the amount of protein in the total membrane fraction. However, insulin treatment down-regulates GLUT1 mRNA and protein expression. Moreover, either insulin or IGF-I transactivates a full-promoter GLUT4-chloramphenicol acetyltransferase gene (CAT) construct transiently transfected to the cells, without affecting GLUT1-CAT activity. In consequence, insulin treatment for 24 h increased by 3-fold the basal glucose uptake. Inhibition of phosphoinositide (PI) 3-kinase activity with chemical agents such as wortmannin or LY294002 partially blocked insulin-induced GLUT4 mRNA accumulation, insulin-induced GLUT4 protein content, GLUT4-CAT transactivation and glucose uptake. Furthermore, co-transfection of brown adipocytes with a dominant-negative form of PI 3-kinase precluded the transactivation of the GLUT4 promoter by insulin. However, inhibition of p70S6 kinase (p70(s6k)) with rapamycin or of mitogen-activated protein kinase (MAPK) with PD098059 does not preclude insulin effects on GLUT4 gene expression or glucose uptake. Our results show for the first time a positive effect of insulin on GLUT4 gene expression in fetal brown adipocytes, suggesting the existence of insulin response element(s) in its promoter. Moreover, PI 3-kinase, but not p70(s6k) or MAPK, is an essential requirement for insulin regulation of GLUT4 gene expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / cytology
  • Adipose Tissue / embryology
  • Adipose Tissue / metabolism*
  • Animals
  • Cells, Cultured
  • Chloramphenicol O-Acetyltransferase / genetics
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Gene Expression Regulation, Developmental*
  • Glucose / metabolism
  • Glucose Transporter Type 1
  • Glucose Transporter Type 4
  • Insulin / pharmacology
  • Insulin / physiology*
  • Insulin-Like Growth Factor I / physiology*
  • MAP Kinase Kinase 1
  • Mitogen-Activated Protein Kinase Kinases*
  • Monosaccharide Transport Proteins / biosynthesis*
  • Monosaccharide Transport Proteins / genetics
  • Muscle Proteins*
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Promoter Regions, Genetic
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Wistar
  • Recombinant Fusion Proteins / biosynthesis
  • Recombinant Fusion Proteins / genetics
  • Ribosomal Protein S6 Kinases / metabolism
  • Up-Regulation

Substances

  • Enzyme Inhibitors
  • Flavonoids
  • Glucose Transporter Type 1
  • Glucose Transporter Type 4
  • Insulin
  • Monosaccharide Transport Proteins
  • Muscle Proteins
  • Phosphoinositide-3 Kinase Inhibitors
  • RNA, Messenger
  • Recombinant Fusion Proteins
  • Slc2a1 protein, rat
  • Slc2a4 protein, rat
  • Insulin-Like Growth Factor I
  • Chloramphenicol O-Acetyltransferase
  • Protein-Tyrosine Kinases
  • Protein Serine-Threonine Kinases
  • Ribosomal Protein S6 Kinases
  • MAP Kinase Kinase 1
  • Mitogen-Activated Protein Kinase Kinases
  • Glucose
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one